GlassScriptPhysician profile
Vuppala V Reddy
NPI 1174612931
$10,261.19
in general payments reported to CMS, 2019-2025
55 companies · $1,171 in 2025
The $1,171 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,602 · 2020: $1,228 · 2021: $1,436 · 2022: $790 · 2023: $1,506 · 2024: $1,528 · 2025: $1,171.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,185 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,185.03 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,346.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,013.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $881.26 | 2019-2025 | |
| Abbvie INC. | $874.33 | 2020-2025 | |
| Amgen INC. | $849.97 | 2019-2025 | Repatha, Otezla, Otezla |
| Astellas Pharma US INC | $463.22 | 2019-2024 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $401.39 | 2019-2025 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $388.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $372.78 | 2019-2025 | |
| Glaxosmithkline, LLC. | $316.09 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Antares Pharma, INC. | $242.69 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Bayer Healthcare Pharmaceuticals INC. | $239.66 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $213.20 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $209.52 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $201.59 | 2019-2025 | Jardiance |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vuppala Reddy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.